dc.contributor.author | Qutranji, Lubna | |
dc.contributor.author | Bakir, Alev | |
dc.contributor.author | Kaya, Eda | |
dc.contributor.author | YILMAZ, YUSUF | |
dc.contributor.author | Alkayyali, Tasnim | |
dc.date.accessioned | 2022-02-18T11:22:28Z | |
dc.date.available | 2022-02-18T11:22:28Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Alkayyali T., Qutranji L., Kaya E., Bakir A., YILMAZ Y., "Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease", ACTA DIABETOLOGICA, cilt.57, sa.5, ss.613-618, 2020 | |
dc.identifier.issn | 0940-5429 | |
dc.identifier.other | av_ef7f3ec3-6059-4086-a728-914b5b261a63 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/181044 | |
dc.identifier.uri | https://doi.org/10.1007/s00592-019-01467-7 | |
dc.description.abstract | Background/aim Simple noninvasive fibrosis scores based on routine blood tests have been increasingly investigated as screening tools in different clinical settings. Here, we sought to examine whether the Fibrosis-4 Index (FIB-4) and the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) could perform differently in diabetic versus non-diabetic patients with biopsy-proven NAFLD. Methods We examined 349 patients with biopsy-proven NAFLD (166 with type 2 diabetes and 183 without). Patients with FIB-4 scores 2.67 or NFS scores 0.676 were considered at low and high risk of advanced fibrosis, respectively. Results A FIB-4 cutoff value of 1.3-which denotes a low risk of advanced fibrosis-had a specificity of 67% in patients with diabetes and 69% in those without. Conversely, a FIB-4 cutoff value of 2.67-which denotes a high risk of advanced fibrosis-had a sensitivity of 22% in patients with diabetes and 0% in those without. NFS performed similar to FIB-4. Conclusion Both FIB-4 and NFS scores have an acceptable clinical utility in the exclusion of advanced fibrosis in patients with NAFLD, regardless of the presence of type 2 diabetes. However, their usefulness in identifying advanced fibrosis is limited-especially in the absence of diabetes. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
dc.subject | Endocrinology | |
dc.subject | Endocrine and Autonomic Systems | |
dc.subject | Endocrinology, Diabetes and Metabolism | |
dc.subject | Life Sciences | |
dc.subject | Health Sciences | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
dc.title | Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease | |
dc.type | Makale | |
dc.relation.journal | ACTA DIABETOLOGICA | |
dc.contributor.department | Marmara Üniversitesi , , | |
dc.identifier.volume | 57 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 613 | |
dc.identifier.endpage | 618 | |
dc.contributor.firstauthorID | 3083384 | |